Skip to main navigation

Main Nav

About Us
Scientific Platform
Our Pipeline
Career Opportunities
Investors & Media

Press Releases

IR Nav

Overview
Press Releases
Events
Presentations
Annual Reports
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
FAQs
Email Alerts
Investor Contact

Shareholder Tools

Press Releases

Year

Gritstone Oncology Announces the Appointment of Dr. Vijay Yabannavar, a Biopharma Leader with Over 30 Years of Experience, as Executive Vice President of Manufacturing and Technical Operations

July 8, 2019

Gritstone Oncology to Present at Two Upcoming Investor Conferences in June

June 5, 2019

Gritstone Oncology to Host Event with Oncology Key Opinion Leaders Discussing Neoantigen-based Immunotherapy During ASCO Annual Meeting

May 30, 2019

Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights

May 13, 2019

Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock

April 24, 2019

Gritstone Oncology Announces Proposed Public Offering of Common Stock

April 22, 2019

Gritstone Oncology Announces Clinical Acceleration of “Off-The-Shelf” Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback

April 22, 2019

Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board

April 4, 2019

Gritstone Oncology to Present at Needham Healthcare Conference

April 3, 2019

Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods

April 2, 2019

Pagination

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Next page
Last page

© 2021 Gritstone Bio |

Footer Links

Privacy Policy
Terms of Use
Contact

socials

Top